Product How it works Pricing Blog FAQ About Contact
Español English
EspañolEnglish
Log inCreate free account
Cytokinetics

Cytokinetics (NASDAQ: CYTK) insider transactions

In the twelve months to 10 November 2026, executives and directors of Cytokinetics reported 85 open-market sales of 748,367 shares ($52.1m) and 0 open-market purchases, by 10 people, according to the Form 4 filings they submitted to the SEC.

Latest transactions

The 20 most recent transactions in Cytokinetics shares reported on Form 4
DateInsiderRoleTransactionSharesPriceHeld afterFiling
3 November 2026Malik Fady IbrahamEVP Research & DevelopmentOption exercise, 10b5-1 plan+3,500$7.80157,402Form 4
3 November 2026Malik Fady IbrahamEVP Research & DevelopmentOpen-market sale, 10b5-1 plan−3,500$62.93153,902Form 4
2 November 2026Blum Robert IPresident & CEOOption exercise, 10b5-1 plan+7,500$10.60286,044Form 4
2 November 2026Blum Robert IPresident & CEOOpen-market sale, 10b5-1 plan−7,500$62.81278,544Form 4
20 October 2026Malik Fady IbrahamEVP Research & DevelopmentOption exercise, 10b5-1 plan+3,500$7.80157,402Form 4
20 October 2026Malik Fady IbrahamEVP Research & DevelopmentOpen-market sale, 10b5-1 plan−3,500$64.01153,902Form 4
16 October 2026Henderson John TDirectorGrant or award+352$63.9278,712Form 4
16 October 2026Wierenga WendellDirectorGrant or award+97$63.9235,660Form 4
16 October 2026Daly James MDirectorGrant or award+195$63.923,585Form 4
16 October 2026Harrington Robert ArthurDirectorGrant or award+195$63.9222,127Form 4
16 October 2026Kaye Edward M. MDDirectorGrant or award+195$63.9210,629Form 4
16 October 2026Wysenski NancyDirectorGrant or award+97$63.9234,089Form 4
12 October 2026Blum Robert IPresident & CEOOption exercise, 10b5-1 plan+7,500$10.60286,044Form 4
12 October 2026Blum Robert IPresident & CEOOpen-market sale, 10b5-1 plan−7,500$62.88278,544Form 4
6 October 2026Malik Fady IbrahamEVP Research & DevelopmentOption exercise, 10b5-1 plan+3,500$7.80157,402Form 4
6 October 2026Malik Fady IbrahamEVP Research & DevelopmentOpen-market sale, 10b5-1 plan−3,500$61.38153,902Form 4
28 September 2026Blum Robert IPresident & CEOOption exercise, 10b5-1 plan+7,500$10.60286,044Form 4
28 September 2026Blum Robert IPresident & CEOOpen-market sale, 10b5-1 plan−7,500$65.46278,544Form 4
22 September 2026Malik Fady IbrahamEVP Research & DevelopmentOption exercise, 10b5-1 plan+3,500$7.80157,402Form 4
22 September 2026Malik Fady IbrahamEVP Research & DevelopmentOpen-market sale, 10b5-1 plan−3,500$68.29153,902Form 4

Names appear as in the filing, surname first. A dash in the price column means the filing reports none, as in grants and gifts.

How to read the table

Only open-market purchases and sales are trades the insider chose to make at the market price, and they are the ones counted in the summary above. Grants, option exercises and shares withheld for tax come from pay plans. A sale marked as a 10b5-1 plan was scheduled in advance under a written plan.

Where each row comes from

From the Form 4 that each executive, director or large shareholder must file with the SEC within two business days of a transaction, read up to 10 November 2026. Each row links to its filing on EDGAR. Only transactions in shares are listed, not derivatives, and amended filings are left out. The accounts of the company are on the Cytokinetics page; the method, in data sources.

Information prepared from the Form 4 filings submitted to the SEC, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.